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Summary
ARDS is characterized by a non-cardiogenic pulmonary edema with bilateral chest radiograph
opacities and hypoxemia refractory to oxygen therapy. It is a common cause of admission to the
ICU due to hypoxemic respiratory failure requiring mechanical ventilation. Corticosteroids are not
recommended in ARDS patients. Rescue therapies alleviate hypoxemia in patients unable to main-
tain reasonable oxygenation: recruitment maneuvers, prone positioning, inhaled nitric oxide, high-
frequency oscillatory ventilation, and extracorporeal membrane oxygenation improve oxygenation,
but their impact on mortality remains unproven. Restrictive fluid management seems to be a
favorable strategy with no significant reduction in 60-d mortality. Future studies are needed to
clarify the efficacy of these therapies on outcomes in patients with severe ARDS, and institution of
these therapies may be considered on a case-by-case basis. Key words: severe ARDS; refractory
hypoxemia; ventilatory setting; rescue therapies; extracorporeal membrane oxygenation; prone position.
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Introduction
ARDS is a life-threatening condition that complicates a
variety of critical illnesses, including sepsis, pneumonia,
pancreatitis, and trauma.1 It is characterized by intense
lung inflammation, progressive microatelectasis, diffuse
alveolar damage, increased pulmonary vascular permea-
bility, increased lung weight, and loss of aerated tissue.2
ARDS is clinically associated with severe hypoxemia, pa-
tient-ventilator asynchrony, and high susceptibility to baro-
trauma and ventilator-induced lung injury (VILI).3
ARDS was first described 50 years ago by Ashbaugh
and Petty4 in a case series of 12 patients who shared the
common features of unusually persistent tachypnea and
hypoxemia, opacification on chest radiographs, and poor
lung compliance, despite different underlying causes. In
1994, the American and European Consensus Conference
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proposed a new definition of ARDS that was globally ac-
cepted.5 In 2012, this definition was revised by an interna-
tional panel of experts and is now referred to as the Berlin
definition of ARDS (Table 1).6 A recent large observational
study7 reported an ARDS prevalence of 10.4% of all ICU
admissions and of 23.4% of all subjects receiving mechanical
ventilation. ARDS appears to be underrecognized, under-
treated, and associated with an especially high mortality rate
of 46.1% for patients with severe ARDS.
The primary target for ARDS treatment is to ensure
adequate gas exchange while minimizing the risk of VILI.
To date, treatment is largely supportive, and mechanical
ventilation remains the cornerstone. Some patients are un-
able to maintain adequate oxygenation despite being sup-
ported with conventional mechanical ventilation, and life-
threatening refractory hypoxemia may occur. Although a
standard definition for refractory hypoxemia is a matter of
ongoing debate, in most reports it has been defined as
having a PaO2  60 mm Hg, with an FIO2 of 0.8–1.0 and
a PEEP  10–20 cm H2O for  12–24 h. Under these
circumstances, physicians may consider a number of support-
ive therapies, which are a final rescue attempt to prevent
severe complications or death from hypoxemia (Fig. 1). Res-
cue therapies are only temporary methods that can support or
replace respiratory function in patients with severe refractory
respiratory failure on conventional mechanical ventilator sup-
port. Although these strategies improve oxygenation, their
impact on mortality remains unproven, and they require a
higher cost in terms of increased risk compared with standard
care. Institution of these therapies may be considered on an
individualized basis, and the choice will often be dictated by
local availability and expertise.8,9
Ventilation and PEEP
In a large study conducted by the ARDS Network,10
mortality was reduced and the number of ventilator-free
days was greater in the group treated with lower tidal
volumes (VT 6 mL/kg of predicted body weight) than in
the group treated with traditional VT. Decreasing plasma
interleukin-6 (IL-6) concentrations, suggested that the
group treated with lower VT had less lung inflammation. A
reduced systemic inflammatory response to lung injury
could contribute to the higher number of days without
organ or system failure and the lower mortality in the
group treated with lung-protective ventilation.10 As com-
pared with conventional ventilation, the protective strategy
was associated with a higher rate of weaning from me-
chanical ventilation and a lower rate of barotrauma in
patients with ARDS, despite the use of higher PEEP levels
and higher mean airway pressures.11 High levels of IL-8,
IL-6, TNF-, IL-1 in bronchoalveolar lavage of patients
with ARDS confirm the relevance of cytokines in the am-
plification of the inflammatory cascade leading to multi-
organ failure and increasing mortality. Ranieri et al12 com-
pared lung-protective ventilation with conventional
ventilator strategy to evaluate the influence of mechanical
ventilation on lung and systemic cytokine levels. The con-
centration of inflammatory mediators was lower 36 h after
randomization in the lung-protective ventilation group than
in the conventional strategy group. This lung-protective
ventilation strategy aims to minimize VILI, which may
result from alveolar overdistention or repeated opening
and closing of individual lung units.
While in the past the choice of a specific mode of me-
chanical ventilation (pressure-controlled vs volume-con-
trolled), was considered relevant for patient outcome, 2
recent meta-analyses were not able to show any significant
difference in mortality, risk of barotrauma, or other phys-
iologic responses.13,14 Despite the use of pressure- and
volume-limited ventilatory strategies, lung injury may still
persist or progress in some patients, resulting in worsening
hypoxemia.15 Limited aerated lung tissue available to re-
ceive tidal ventilation consequently leads to regional hy-
perinflation and excessive stress; insufficient PEEP leads
to excessive sheer injury.
Dependent lung regions of patients with ARDS contrib-
ute significantly to the development of hypoxemia because
of shunts in perfused, nonaerated alveoli. Strategies to
open this collapsed lung tissue may improve oxygenation
and further reduce mortality. This especially may be an
issue in patients receiving low VT ventilation in which a
substantial portion of the lung may remain collapsed due
to pressure and volume limitations. Terragni et al16 ob-
tained pulmonary computed tomography at end-expiration
and end-inspiration for 30 subjects treated with lung-pro-
tective ventilation. One third of subjects experienced sub-
stantial tidal hyperinflation with VT 6 mL/kg predicted
body weight and plateau pressure (Pplat)  30 cm H2O. In
these subjects, the concentration of inflammatory media-
tors was higher and the number of ventilator-free days was
lower than in the two thirds of subjects who experienced
Table 1. The Berlin Definition of ARDS
Factors Criteria
Timing Within 1 week of a known clinical insult or new
worsening respiratory symptoms
Chest imaging Bilateral opacities not fully explained by
effusions lobar/lung collapse, or nodules
Origin of edema Pulmonary edema not fully explained by cardiac
failure or fluid overload; objective assessment
(eg, echocardiography) is required to exclude
hydrostatic edema if no risk factor is present
Oxygenation Requires CPAP/PEEP  5 cm H2O
Mild PaO2/FIO2  201–300 mm Hg
Moderate PaO2/FIO2  101–200 mm Hg
Severe PaO2/FIO2  100 mm Hg
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less tidal hyperinflation. Pplat  28 cm H2O were associ-
ated with less tidal hyperinflation than values of Pplat of
28–30 cm H2O. Pplat 28 cm H2O seems to be associated
with the more protective ventilatory settings. The ARDS
Network settings may not be sufficient to minimize VILI
in patients with ARDS whose disease process is charac-
terized by a distribution of pulmonary lesions with a small,
nondependent, normally aerated compartment and a large,
dependent, nonaerated compartment. The proportion of
nonaerated lung may be recruited by applying higher lev-
els of PEEP than traditionally used (5–12 cm H2O) in the
management of patients with ARDS.17,18 Amato et al19
postulated that cyclic strain predicts lung injury better than
VT. The functional lung size during disease is better quan-
tified by the compliance of the respiratory system than by
predicted body weight. Under such conditions, especially
when the compliance of the respiratory system varies con-
siderably among patients, cyclic strain, VILI, and survival
should all be correlated with driving pressure rather than
with VT.
Although several experimental and observational stud-
ies found a beneficial effect for the use of higher PEEP
in ARDS, 3 randomized trials, published between 2004
and 2008, did not show any difference in outcome be-
tween a low and a high PEEP ventilator strategy.20 –22
However, when combining these data and considering
only the subgroup of the most severe subjects (PaO2/FIO2
 200 mm Hg), the use of higher PEEP levels significantly
decreased mortality.23 This suggests that the greater the
severity (and the greater the amount of lung edema), the
greater the positive effect of PEEP in reducing VILI. This
has also been confirmed in an observational study, in which
higher PEEP levels significantly reduced the opening and
closing effects only in subjects with higher recruitability.24
However, the relationship between lung edema and re-
cruitability has been questioned by Cressoni et al,25 who
found that the PEEP levels necessary to keep the lung
open were independent from total lung recruitability. These
results suggest that recruitability depends also on the na-
ture of edema, time of onset, and distribution of the dis-
ease within lung parenchyma.
Although several approaches have been proposed to tai-
lor PEEP for the individual patient, the most common is to
titrate PEEP according to an oxygenation/saturation target
based on a PEEP/FIO2 table.21 In 1975, Suter et al16 coined
the term best PEEP as the point at which the degree of
lung recruitment is balanced with the risk of concomitant
overdistention. The basis for determining the best PEEP is
the quantification of recruitment: to increase PEEP by main-
taining a constant VT, not exceeding a safe limit of Pplat
26–28 cm H2O, or, after a recruitment maneuver, to de-
crease PEEP until a reduction of compliance appears.27 In
a pooled sample of 3,562 subjects with ARDS ventilated
with different combinations of VT and PEEP, the protec-
tive effects of higher PEEP were only seen when this was
associated with decreased driving pressures, with a cutoff
for increased mortality at a driving pressure of 15 cm H2O.19
Most important to this discussion was the fact that the
relationship between mortality and high Pplat was observed
only when driving pressure also was above 15 cm H2O.
The airway driving pressure was the factor most associ-
ated with the outcome: higher mortality was only found
when higher Pplat values were observed in subjects with
higher driving pressures.
Fig. 1. Rescue therapy in increasing hypoxemia severity. Green indicates mild severity, yellow moderate severity, and red severe. ECMO 
extracorporeal membrane oxygenation, HFOV  high-frequency oscillatory ventilation, INO  inhaled nitric oxide, NMBA  neuromuscular
blocking agent.
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Many techniques have been proposed to monitor lung
recruitment, such as ultrasonography, electric impedance
tomography, respiratory mechanics measurements, nitro-
gen washout techniques, and quantitative computed to-
mography scan, but none has yet gained general consensus
or become routinely used in clinical settings.28–32
Despite the possible uncertainties regarding the end-
expiratory absolute esophageal pressure as a reliable esti-
mation of the pleural pressure, better oxygenation and com-
pliance was achieved when PEEP was set according to an
end-expiratory transpulmonary pressure of 0–10 cm H2O.33
An alternative to using the absolute value of esophageal
pressure is to monitor how it changes due to adjustments
in PEEP and VT. This has been used to compute total
end-inspiratory transpulmonary pressure, and it is a better
marker of lung stress compared with Pplat in the presence
of alterations in chest wall elastance. Setting high PEEP
levels (15–18 mm Hg) should be accompanied by thor-
ough hemodynamic assessment and might additionally be
justified by transpulmonary pressure measurements and
assessment of physiological dead space by volumetric cap-
nography.34,35
Recruitment Maneuvers
Recruitment maneuvers are used as a strategy to im-
prove oxygenation and reduce the risk of atelectrauma in
patients with ARDS by re-opening and stabilizing col-
lapsed lung regions.18 Several recruitment maneuvers have
been proposed, including sustained inflations with CPAP
values of 35–50 cm H2O for 20–40 s, incremental peak
inspiratory pressures, lower VT (with sighs), intermittent
sighs, stepwise increments in PEEP, and slow increases of
inspiratory pressure to 40 cm H2O.36 Recruitment maneu-
vers attempt to increase the amount of aerated lung tissue
to improve gas exchange. However, these may expose
regions of healthy lung tissue to increased pressure and the
risk of overdistention.
Several studies have shown improved gas exchange with
recruitment maneuvers, but this did not translate into im-
proved mortality. Benefits from recruitment maneuvers
tend to be short-lived, and the increased airway pressure
results in transient adverse events (eg, hypotension, hy-
poxemia) in a minority of patients. For example, in a re-
cent systematic review, hypotension and decreased satu-
ration occurred in 12% and 8% of subjects, respectively,
during or after such maneuvers.18,36 However, persistent
and severe adverse events related to recruitment maneu-
vers, such as the development of pneumothorax, remain
rare.37 Moreover, studies to date have not elucidated the
optimal technique, timing, and frequency of recruitment
maneuvers. On the basis of currently available data, al-
though routine recruitment maneuvers are not recom-
mended to treat ARDS, such maneuvers can dramatically
improve oxygenation in certain patients and should be
considered as rescue therapy in patients with life-threat-
ening refractory hypoxemia.38
Steroids
Steroids have positive immunomodulatory effects on
inflammatory imbalance, reducing edema, hyaline mem-
brane formation, surfactant depletion, and alveolar capil-
lary membrane damage.39 High-dose and short-duration
therapy (methylprednisolone 30 mg/kg/d) have demon-
strated no improvement in mortality and an increased risk
of infection.40 A recent meta-analysis investigating lower
doses, instituted earlier and for longer duration, appeared
to demonstrate improvements in lung function and de-
creased mortality.41 However, conclusive evidence about
the use of steroids is lacking. Corticosteroids are not rec-
ommended as rescue therapy in patients with ARDS, be-
cause of improvements have been observed to be delayed
and inconsistent.42
Fluid Management
ARDS is a protein-rich inflammatory lung edema into
the interstitial space, often associated with a hydrostatic
component. The increase in lung weight produces com-
pression atelectasis and impairs lung mechanics and gas
exchange. Pulmonary hypertension may be easily associ-
ated with increased pulmonary capillary pressure and car-
diac failure. While the common mechanisms that cause
edema are surgery and pleural effusion, lymphatic flow
and capillary reabsorption into the venous side of the pul-
monary capillary network are impaired by the positive
intrathoracic pressure associated with mechanical ventila-
tion.43 Excessive fluid administration leads to increased
extravascular lung water, which is a poor prognostic marker
in ARDS. Optimal fluid management provides dry lungs
while maintaining organ perfusion.
An ARDS Network trial44 was designed to investigate
risks and benefits of a fluid management protocol. Sub-
jects with ARDS were randomized to conservative or lib-
eral groups. The conservative group showed improved lung
function compared with the liberal group, with fewer days
on ventilation and ICU days without increasing non-pul-
monary organ failures. There was no significant reduction
in 60-d mortality. Over the first 7 d, the liberal group had
a fluid balance that increased approximately 1 L/d, whereas
those in the conservative group fluid balance remained
neutral.
In the subgroup of patients who are hypoproteinemic,
there may be a role for accelerated edema clearance when
pulmonary capillary permeability and hemodynamic sta-
bility is restored, because hypoproteinemic patients may
be safely treated with a combination of albumin and fu-
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rosemide. Diuresis, weight loss, and normalization of se-
rum protein concentrations may be achieved, and, over the
first 24–48 h of therapy, the PaO2/FIO2 increased by
 60 mm Hg.45 A follow-up study of the same group also
reported that PaO2/FIO2 increased by  40 mm Hg over
24–72 h compared to a decrease of 13–24 mm Hg in the
placebo group.46 These represent substantial improvements
in oxygenation.
Neuromuscular Blocking Agents
Spontaneous breathing seems to be dangerous in pa-
tients with severe ARDS, whereas it appears to be bene-
ficial in patients with mild to moderate ARDS. Neuromus-
cular blocking agents (NMBAs) should be reserved for the
most severe cases to ensure patient–ventilator synchrony
and prevent generation of a dangerously high transpulmo-
nary pressure and VILI.47
Treatment with a continuous infusion of cisatracurium
for 48 h early in the course of severe ARDS reduces 90-d
mortality and barotraumas. It also increases the number of
ventilator-free days and the number of days outside the
ICU. In this context, the risk of ICU-acquired weakness is
not increased.48 Early use of NMBAs decreases the pro-
inflammatory response associated with ARDS and me-
chanical ventilation. The precise mechanism resulting in
improved outcomes is not clear. Better synchrony may
lead to more uniform lung recruitment and improved com-
pliance, gas exchange, and systemic oxygenation. With
respect to lung inflammation, it is plausible that improved
control of inspiratory volumes and pressures reduces vo-
lutrauma, while better control of expiratory volumes and
pressures reduces atelectrauma; the result is less pulmo-
nary and systemic inflammation.49 These potential bene-
fits must be weighed against prevailing concerns about
NMBA therapy, including progressive atelectasis due to
loss of diaphragmatic tone (with resultant hypoxemia) and,
most important, ICU-acquired weakness.50
High-Frequency Oscillatory Ventilation
High-frequency oscillatory ventilation (HFOV) is a non-
conventional mode that has been proposed to achieve the
targets of protective ventilation with very low VT (equal to
or less than the anatomical dead space) at a very high rate
(3–6 Hz); sinusoidal flow oscillations are applied around
a relatively constant mean airway pressure (P aw). This strat-
egy avoids overdistention of alveoli by delivering low VT
(1–3 mL/kg), averting volutrauma, prevents end-expira-
tory alveolar collapse, and maintains alveolar recruitment
by applying a constant P aw to facilitate lung recruitment.51
HFOV theoretically achieves all goals pursued by lung-
protective ventilation strategies; however, 2 large random-
ized clinical trials failed to prove any clinical benefit when
HFOV was applied in adults with moderate to severe ARDS
as compared with a strategy with low VT, high PEEP, and
limited Pplat. Young et al52 did not show any difference in
mortality with HFOV compared to conventional mechan-
ical ventilation, whereas Ferguson et al53 reported an in-
crease in mortality with HFOV. High P aw suggests that
overdistention of some lung regions without increased aer-
ation of collapsed or flooded alveoli occurred, especially
among subjects with heterogeneous and nonrecruitable
lung. Increased mortality might also be due to the hemo-
dynamic compromise implied by increased requirement of
vasopressors and by the right ventricular failure secondary
to a considerable increase in afterload. HFOV should not
be used routinely in place of conventional lung-protective
ventilation, and it should be reserved as a rescue therapy
for those patients with refractory hypoxemia and in se-
lected cases of severe ARDS.54
The assessment of transpulmonary pressure by measur-
ing esophageal pressure may represent a valid strategy to
adopt more physiological P aw, reducing the risk of further
lung injury and leading to maximal lung recruitment and
minimal overdistention.55 The EPOCH Study (Clinical
Trials.gov NCT02342756) is using this approach to adjust
PEEP during conventional mechanical ventilation and P aw
during HFOV.56
Selective Pulmonary Vasodilators
Selective pulmonary vasodilators are commonly utilized
for their therapeutic role in improving oxygenation in pa-
tients who have developed refractory hypoxemia in
ARDS.57 These agents localize the drug to lung paren-
chyma capable of ventilation, improving ventilation-per-
fusion mismatch. Selective pulmonary vasodilators com-
monly used include inhaled nitric oxide (INO) and inhaled
epoprostenol, a prostacyclin.
INO is a local vasodilator of capillary vessels in well-
aerated alveoli, and it improves the ventilation-perfusion
match in patients with ARDS and reduces pulmonary vas-
cular resistance, which improves right ventricular output.58
The routine use of INO in ARDS is not recommended on
the basis of current evidence, but it is frequently used in
many institutions. The use of INO in subjects with ARDS
showed no significant reduction in mortality.59 Use of INO
could be considered when patients appear to be at great
risk of imminent death from hypoxemia despite all other
treatments. INO did not show significant beneficial effects
on the duration of mechanical ventilation and stay in the
ICU compared to the control group.59 Although INO
improves oxygenation in the first 24 h by reducing venti-
lation-perfusion mismatch, over time it will induce vaso-
dilatation of poorly ventilated areas, increasing ventila-
tion-perfusion mismatch.60
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Improved oxygenation is not associated with increased
survival rates because the temporary improvement of ox-
ygenation does not indicate improved lung function, re-
duction of lung injury, or resolution of the underlying
cause of ARDS, including coexisting multi-organ dam-
age.61 With the use of INO, the difference of pulmonary
arterial pressure was initially significant on the first day
but no longer present on days 2–4.61 Nitric oxide is as an
important regulator of renal vascular tone and a modulator
of glomerular function. When INO was first introduced,
formation of methaemogloblin, production of reactive ni-
trogen species, hypotension, and platelet inhibition were
the main collateral effects, while nephrotoxicity was not a
major concern.62,63 Different studies demonstrated that INO
increased the risk of renal injury among adult subjects
with ARDS and potentially doubled the risk of renal re-
placement therapy.64 Therefore, changes in nitric oxide
production could cause acute renal injury by altering the
function of mitochondria, various enzymes, and deoxyri-
bonucleic acid. Despite insufficient randomized controlled
trials or meta-analyses, the combination therapies with
prone positioning or HFOV may help in selected groups of
patients or as a salvage therapy because they can enhance
the effect of INO better than monotherapy alone.65
Inhaled epoprostenol has been suggested as an alterna-
tive to INO due to its similar efficacy, lower potential for
systemic side effects, ease of administration, and substan-
tially lower cost. Inhaled epoprostenol has been shown to
significantly reduce pulmonary artery pressure and increase
oxygenation. However, prostacyclin administration is tech-
nically challenging given its short half-life and suscepti-
bility to photograph degradation.66 Since it was first pub-
licized for the treatment of ARDS in 1993, efficacy data
are lacking.57,67 Literature evaluating its use is lacking,
and no studies have evaluated mortality as a primary end
point. While commonly used as a therapy of final resort, a
gap in the literature led to controversy surrounding inhaled
epoprostenol with regard to optimal dosing and safety, as
well as the target patient population.68,69 Iloprost, another
selective pulmonary vasodilator traditionally used for treat-
ment of pulmonary hypertension, has theoretical benefits
in patients with ARDS, but there is minimal evidence to
support its use for this indication.70
Prone Position
Prone position was first described 40 years ago as an
alternative strategy to improve oxygenation in patients with
ARDS.71 Several mechanisms have been proposed to ex-
plain this effect, including a redistribution of lung densi-
ties with a recruitment of dorsal regions, an increase in
chest-wall elastance, a reduction in alveolar shunt, and a
better ventilation/perfusion ratio. A more favorable distri-
bution of stress and strain across a wider and more ho-
mogenous territory (due to chest wall/lung shape matching
of ventilation) reduces VILI and reverse right heart failure.
As a consequence of lung recruitment, the reversal of hy-
poxemia and the reduction in driving pressure are the most
reasonable explanations for the reduction in pulmonary
vascular resistance and right heart dimensions during prone
position.72 The shift in gravitational forces reduces atelec-
tasis and minimizes compression of lung parenchyma by
the heart and mediastinal structures, resulting in improved
ventilation–perfusion matching.73
Earlier randomized trials showed inconsistent mortality
benefit of prone positioning; however, these studies in-
cluded all subjects with ARDS (from mild to severe), main-
tained prone position for 6 h/d, and did not apply protec-
tive mechanical ventilation.74,75 Despite these limitations,
the survival rate increased among subjects with most se-
vere ARDS treated in prone position.74 Subsequently, 2
trials, which enrolled more severe hypoxemic subjects with
a longer period of prone positioning (20 h/d), did not show
any beneficial effects.76,77 However, a meta-analysis of
previous studies suggested a significant survival benefit
for subjects with PaO2/FIO2  140 mm Hg at admission.78
The PROSEVA trial79 was a multi-center randomized con-
trolled trial on early application of prolonged prone posi-
tion ( 16 h/d) in subjects with severe ARDS. In this trial,
ARDS severity was defined as PaO2/FIO2  150 with PEEP
 5 cm H2O, FIO2  0.6, with an average VT of 6.1 mL/kg
of predicted body weight. The PROSEVA trial showed a
major decrease in mortality rate at 28 d and 90 d in sub-
jects treated with prone positioning. Early initiation of
prone therapy appears to be an important factor for suc-
cess. The process of moving a patient to a prone position
can be labor-intensive and increases the risk of accidental
removal of the endotracheal tube, drains, or catheters, as
well as the development of pressure sores.72 Although prone
positioning presents some technical challenges, when it is
performed by a skilled team, the adverse effects are rela-
tively low and they are significantly overcome by the ben-
eficial effects.
Contraindications to prone positioning must be consid-
ered, such as increased intracranial pressure or decreased
cerebral perfusion, immediate need for a surgical or inter-
ventional procedure, recent thoracic surgery, recent facial
trauma or surgery, hemodynamic instability, pregnancy or
abdominal compartment syndrome, and unstable fractures
of the spine, pelvis, or femur.80
Extracorporeal Membrane Oxygenation
In severe hypoxemia resistant to conventional treatment,
including low-volume, low-pressure ventilation, prone po-
sition, INO, and HFOV, extracorporeal membrane oxy-
genation (ECMO) can be used as a rescue therapy by
securing oxygenation as well as carbon dioxide removal
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while the lungs are resting with low ventilator pressure
and low oxygen fraction.9
ECMO support is commonly performed via veno-ve-
nous access in which blood is drained via the superior or
inferior vena cava and reinfused in the right atrium. ECMO
is indicated when PaO2/FIO2 is  80, when FIO2 is  90%,
and when the lung injury score is 3–4; in this case, the risk
of mortality exceeds 80%.81 In the Berlin definition of
ARDS, ECMO is proposed as a rescue therapy for severe
hypoxemia when PaO2/FIO2 is  50. ECMO is considered
when Pplat exceeds 32 cm H2O, FIO2 100%, SpO2 90%,
or pH  7.2.82
Indeed, once patients are on ECMO, blood can be well
oxygenated with normal PaCO2 and neutral pH; the goal of
lung-protective ventilation is achieved and VILI is mini-
mized.83 In patients with particularly severe ARDS who
undergo ECMO, VT is significantly reduced by almost
half, which leads to significant reduction in Pplat and de-
recruitment as PEEP remains stable.84 It can take a long
time for some patients to re-open their lungs, and there
could be a difficult balance between the risk of injury from
lung overdistention and the risk of lung under-recruitment.84
Over the past few decades, most trials evaluating ECMO
demonstrated no benefit because of several factors, includ-
ing the prolonged interval between ARDS onset and as-
sistance initiation, the poor oxygenation and CO2 removal
capacities of devices used, and the high rate of technical
complications such as significant bleeding resulting from
intense anticoagulation required to overcome the poor bio-
compatibility of the circuits.85 Recently, however, signif-
icant progress has been made in the manufacture of ECMO
circuits that are more biocompatible, perform at a higher
level, and are more durable.
The United Kingdom-based Conventional Ventilation
or ECMO for Severe Adult Respiratory Failure (CESAR)
trial86 and the good outcomes of subjects who received the
latest generation of ECMO as rescue therapy during the
influenza A (H1N1) influenza pandemic have reignited
interest in ECMO for patients with severe ARDS. The
CESAR trial in adult subjects with ARDS demonstrated an
increase in 6-month survival from 50% to 63% in the
ECMO group, but the difference compared to the control
group was not significant. When combining the mortality
and the 6-month disability end points, the difference be-
came significant in favor of the ECMO group.86 However,
it is not possible to conclude that ECMO is superior to
mechanical ventilation, because all subjects requiring
ECMO were allocated only in one skilled center and the
control group was not ventilated with a lung-protective
strategy.87,88
Nevertheless, ECMO treatment has a place in clinical
practice, as indicated by the Extracorporeal Life Sup-
port Organization International Registry Report, in which
the number of adult ECMO treatments are expanding.89
The currently ongoing ECMO to Rescue Lung Injury in
Severe ARDS trial is an international, multi-center, ran-
domized controlled trial comparing conventional me-
chanical ventilation with prone positioning to ECMO in
subjects with very severe ARDS (ie, PaO2/FIO280 mm Hg).90
Early initiation of an ECMO strategy might decrease mortal-
ity from 45–50% to  20%, with potentially less cognitive
and psychiatric impairment and improved health-related qual-
ity of life in long-term survivors.91 The possible benefits of
extracorporeal support have to be balanced against dangerous
complications such as bleeding, thrombosis, infection, and
distal limb ischemia.83 There is no absolute contraindication
for ECMO; all cases have to be discussed, and indications
and limits will likely change as future studies are performed.
Summary
ARDS is a syndrome caused by different diseases and
leads to life-threatening refractory hypoxemia. A contin-
uous escalation of therapies may be considered on an
individualized basis. Despite several decades of investigation
into potential treatment strategies, use of lung-protective ven-
tilation with VT of 6 mL/kg predicted body weight and Pplat
 30 cm H2O remains the only proven therapy to decrease
mortality in ARDS. An oxygenation/saturation target based
on a PEEP/FIO2 table is a common approach to set PEEP,
but a relationship between mortality and high Pplat was
observed only when driving pressure also was above
15 cm H2O. In patients with ARDS, recruitment maneu-
vers improve oxygenation, but this is a temporary ap-
proach that doesn’t improve mortality. Evidence support-
ing steroid use is lacking, and a conservative fluid balance
is not superior to a liberal one. NMBAs ensure uniform
lung recruitment, prevent generation of dangerous high
transpulmonary pressure, and decrease the pro-inflamma-
tory response associated with ARDS, but this approach
must be provided within the first 48 h to prevent dia-
phragm atrophy and ICU-acquired weakness. HFOV the-
oretically achieves all of the goals of lung-protective ven-
tilation strategies, however, randomized clinical trials failed
to prove any clinical benefit. INO temporarily improves
oxygenation, but it is not associated with an increased
survival rate and hasn’t shown any benefit to lung func-
tion. Prone positioning in patients with severe ARDS pro-
motes a shift in gravitational forces, minimizes compres-
sion of lung parenchyma by the heart and mediastinal
structures, and improves ventilation–perfusion matching.
ECMO is being increasingly used to support critically ill
adults who have failed conventional management, and it
may be an effective salvage treatment for patients with
ARDS presenting with rapid refractory respiratory failure;
however, controlled trials are needed to better define in-
dications and best practices for this therapy.
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